Table 1: Distribution of the study population by gender for each ART regimen.
|
Women |
Men |
Total n (%) |
||
n (%) |
Mean Age |
n(%) |
Mean Age |
||
AZT + 3TC + NVP |
16 (76.2) |
42.2 ± 12.2 |
5 (23.8) |
39.0 ± 9.3 |
21 (100) |
AZT + TNF + NVP |
5 (71.5) |
47.2 ± 10.8 |
2 (28.5) |
35.5 ± 12.0 |
7 (100) |
3TC + TNF + EMB |
14 (87.5) |
40.0 ± 9.9 |
2 (12.5) |
49.0 ± 11.2 |
16 (100) |
D4T30 + 3TC + EFV |
8 (80) |
45.0 ± 12.6 |
2 (20) |
39.5 ± 6.3 |
10 (100) |
D4T40 + 3TC + NVP |
9 (75) |
45.1 ± 12.0 |
3 (25) |
36.6 ± 7.5 |
12 (100) |
ABC + 3TC + EFV |
2 (66.7) |
41.0 ± 15.5 |
1 (33.3) |
60.0 |
3 (100) |
TNF + 3TC + EFV |
47 (63.5) |
41.4 ± 11.2 |
27 (36.5) |
43.0 ± 10.3 |
74 (100) |
TNF + 3TC + EFV + CTM |
20 (71.4) |
41.6 ± 11.8 |
8 (28.6) |
48.0 ± 5.3 |
28 (100) |
TNF + 3TC + EFV + INH |
6 (100) |
45.4 ± 8.6 |
0 (0.0) |
NA |
6 (100) |
TNF + 3TC + EFV + CTM + INH |
3 (50) |
41.7 ± 3.1 |
3 (50.0) |
39.3 ± 8.9 |
6 (100) |
TNF + 3TC |
4 (100) |
44.0 ± 6.6 |
0 (0.0) |
NA |
4 (100) |
All regimen |
134 (71.66) |
42.3 ± 11.0 |
53 (28.34) |
42.9 ± 10.0 |
187 (100) |
NA: Not Applicable.